AR118997A1 - Partículas virales modificadas y usos de estas - Google Patents
Partículas virales modificadas y usos de estasInfo
- Publication number
- AR118997A1 AR118997A1 ARP200101465A ARP200101465A AR118997A1 AR 118997 A1 AR118997 A1 AR 118997A1 AR P200101465 A ARP200101465 A AR P200101465A AR P200101465 A ARP200101465 A AR P200101465A AR 118997 A1 AR118997 A1 AR 118997A1
- Authority
- AR
- Argentina
- Prior art keywords
- aav
- particles
- viral particles
- modified viral
- current therapeutic
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 4
- 230000003612 virological effect Effects 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000011277 treatment modality Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852791P | 2019-05-24 | 2019-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118997A1 true AR118997A1 (es) | 2021-11-17 |
Family
ID=71094822
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101465A AR118997A1 (es) | 2019-05-24 | 2020-05-22 | Partículas virales modificadas y usos de estas |
| ARP210103220A AR124119A2 (es) | 2019-05-24 | 2021-11-19 | Partículas virales modificadas y usos de estas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103220A AR124119A2 (es) | 2019-05-24 | 2021-11-19 | Partículas virales modificadas y usos de estas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220241430A1 (enExample) |
| EP (1) | EP3976631A1 (enExample) |
| JP (3) | JP2022533438A (enExample) |
| KR (1) | KR20220011664A (enExample) |
| CN (2) | CN113874386A (enExample) |
| AR (2) | AR118997A1 (enExample) |
| AU (1) | AU2020283537A1 (enExample) |
| BR (1) | BR112021023692A2 (enExample) |
| CA (1) | CA3140386A1 (enExample) |
| CL (2) | CL2021003096A1 (enExample) |
| CO (1) | CO2021017692A2 (enExample) |
| IL (1) | IL288233A (enExample) |
| MA (1) | MA56035A (enExample) |
| MX (1) | MX2021014338A (enExample) |
| PE (1) | PE20212357A1 (enExample) |
| PH (1) | PH12021552887A1 (enExample) |
| SG (1) | SG11202112917PA (enExample) |
| TW (1) | TW202110869A (enExample) |
| WO (1) | WO2020242984A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019227910B2 (en) | 2018-02-28 | 2025-07-17 | The Regents Of The University Of California | A modular system for gene and protein delivery based on AAV |
| JP2022533438A (ja) * | 2019-05-24 | 2022-07-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改変ウイルス粒子およびその使用 |
| US20240124892A1 (en) * | 2021-03-02 | 2024-04-18 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Adeno-associated viruses and methods and materials for making and using adeno-associated viruses |
| WO2022232575A1 (en) * | 2021-04-30 | 2022-11-03 | Duke University | Compositions comprising adeno-associated virus chimera capsid proteins and methods of using the same |
| CA3222914A1 (en) * | 2021-06-23 | 2022-12-29 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| US20250302998A1 (en) | 2022-05-09 | 2025-10-02 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| EP4536836A1 (en) | 2022-06-07 | 2025-04-16 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2025042462A2 (en) * | 2023-08-24 | 2025-02-27 | Ohio State Innovation Foundation | Assays and methods for quality control of genome packaging for gene therapy |
| TW202528546A (zh) * | 2023-09-07 | 2025-07-16 | 美商再生元醫藥公司 | 經共價表面修飾之腺相關病毒的生產及純化 |
| TW202540433A (zh) * | 2023-11-21 | 2025-10-16 | 美商再生元醫藥公司 | 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化 |
| WO2026037757A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Modified aav particles |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2224907A1 (en) * | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
| WO1998011244A2 (en) | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| WO1999061601A2 (en) | 1998-05-28 | 1999-12-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav5 vector and uses thereof |
| ATE362542T1 (de) | 1998-11-05 | 2007-06-15 | Univ Pennsylvania | Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten |
| MX359371B (es) * | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
| ES2724975T3 (es) | 2009-12-10 | 2019-09-18 | Regeneron Pharma | Ratones que producen anticuerpos de cadena pesada |
| GB201002362D0 (en) | 2010-02-11 | 2010-03-31 | Isis Innovation | Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds |
| ES2926774T3 (es) * | 2013-03-15 | 2022-10-28 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores AAV de doble unión de glicano |
| CA2942289C (en) * | 2014-03-10 | 2024-05-21 | Uniqure Ip B.V. | Further improved aav vectors produced in insect cells |
| CA3124228C (en) | 2014-03-21 | 2024-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| EP3151866B1 (en) * | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US10550405B2 (en) * | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| PE20200488A1 (es) | 2017-06-27 | 2020-03-03 | Regeneron Pharma | Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas |
| LT3645553T (lt) * | 2017-06-27 | 2023-04-25 | Regeneron Pharmaceuticals, Inc. | Modifikuoto tropizmo rekombinantinės viruso dalelės ir jų panaudojimas genetinės medžiagos tiksliniam įvedimui į žmogaus ląsteles |
| AU2019227910B2 (en) * | 2018-02-28 | 2025-07-17 | The Regents Of The University Of California | A modular system for gene and protein delivery based on AAV |
| JP2022533438A (ja) * | 2019-05-24 | 2022-07-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改変ウイルス粒子およびその使用 |
-
2020
- 2020-05-22 JP JP2021569402A patent/JP2022533438A/ja active Pending
- 2020-05-22 PE PE2021001934A patent/PE20212357A1/es unknown
- 2020-05-22 AU AU2020283537A patent/AU2020283537A1/en active Pending
- 2020-05-22 KR KR1020217041074A patent/KR20220011664A/ko active Pending
- 2020-05-22 TW TW109117155A patent/TW202110869A/zh unknown
- 2020-05-22 SG SG11202112917PA patent/SG11202112917PA/en unknown
- 2020-05-22 CA CA3140386A patent/CA3140386A1/en active Pending
- 2020-05-22 AR ARP200101465A patent/AR118997A1/es unknown
- 2020-05-22 PH PH1/2021/552887A patent/PH12021552887A1/en unknown
- 2020-05-22 MX MX2021014338A patent/MX2021014338A/es unknown
- 2020-05-22 WO PCT/US2020/034328 patent/WO2020242984A1/en not_active Ceased
- 2020-05-22 CN CN202080038612.3A patent/CN113874386A/zh active Pending
- 2020-05-22 EP EP20733099.4A patent/EP3976631A1/en active Pending
- 2020-05-22 US US17/612,669 patent/US20220241430A1/en active Pending
- 2020-05-22 MA MA056035A patent/MA56035A/fr unknown
- 2020-05-22 BR BR112021023692A patent/BR112021023692A2/pt unknown
- 2020-05-22 CN CN202210622571.3A patent/CN114989267A/zh active Pending
-
2021
- 2021-11-18 IL IL288233A patent/IL288233A/en unknown
- 2021-11-19 AR ARP210103220A patent/AR124119A2/es unknown
- 2021-11-23 CL CL2021003096A patent/CL2021003096A1/es unknown
- 2021-12-22 CO CONC2021/0017692A patent/CO2021017692A2/es unknown
-
2023
- 2023-03-03 CL CL2023000629A patent/CL2023000629A1/es unknown
-
2024
- 2024-11-11 JP JP2024196799A patent/JP2025032110A/ja active Pending
-
2025
- 2025-05-22 JP JP2025085876A patent/JP2025119015A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12021552887A1 (en) | 2022-09-05 |
| JP2022533438A (ja) | 2022-07-22 |
| AR124119A2 (es) | 2023-02-15 |
| JP2025032110A (ja) | 2025-03-11 |
| SG11202112917PA (en) | 2021-12-30 |
| PE20212357A1 (es) | 2021-12-17 |
| CO2021017692A2 (es) | 2022-01-17 |
| TW202110869A (zh) | 2021-03-16 |
| CL2023000629A1 (es) | 2023-10-20 |
| CL2021003096A1 (es) | 2022-09-20 |
| AU2020283537A1 (en) | 2021-12-16 |
| WO2020242984A9 (en) | 2021-01-14 |
| MA56035A (fr) | 2022-04-06 |
| BR112021023692A2 (pt) | 2022-01-04 |
| MX2021014338A (es) | 2022-01-06 |
| JP2025119015A (ja) | 2025-08-13 |
| WO2020242984A1 (en) | 2020-12-03 |
| CA3140386A1 (en) | 2020-12-03 |
| US20220241430A1 (en) | 2022-08-04 |
| IL288233A (en) | 2022-01-01 |
| CN114989267A (zh) | 2022-09-02 |
| KR20220011664A (ko) | 2022-01-28 |
| EP3976631A1 (en) | 2022-04-06 |
| CN113874386A (zh) | 2021-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118997A1 (es) | Partículas virales modificadas y usos de estas | |
| Rintoul et al. | ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic | |
| PE20211419A1 (es) | Vectores virales recombinantes y acidos nucleicos para producirlos | |
| CL2020000728A1 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas. | |
| CL2018001522A1 (es) | Focalización de péptidos para dirigir virus adenoasociados (aavs) | |
| CL2018003196A1 (es) | Cápsides variantes de virus adenoasociados y métodos de uso de estas. | |
| PE20210915A1 (es) | Capsides variantes de virus adenoasociados y su uso para inhibir la angiogenesis | |
| DOP2016000237A (es) | Terapia genica para la retinitis pigmentaria | |
| MX2023003699A (es) | Virus adenoasociados para el suministro ocular de genoterapia. | |
| MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
| AR055603A1 (es) | Vacuna contra la infeccion por virus del dengue | |
| McWilliams et al. | Pseudovirus rVSVΔG-ZEBOV-GP infects neurons in retina and CNS, causing apoptosis and neurodegeneration in neonatal mice | |
| CL2022000939A1 (es) | Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c | |
| MX2017014257A (es) | Metodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con celulas t. | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| Wang et al. | Recombinant rabies virus expressing IFNα1 enhanced immune responses resulting in its attenuation and stronger immunogenicity | |
| CO2017007383A2 (es) | Métodos para utilizar oligonucleótidos antisentido para smad7 | |
| EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
| Ellerhoff et al. | Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus | |
| NI201700080A (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas. | |
| Summerfield | Factors involved in type I interferon responses during porcine virus infections | |
| Silva et al. | Photobiomodulation mitigates Bothrops jararacussu venom-induced damage in myoblast cells by enhancing myogenic factors and reducing cytokine production | |
| EA201401352A1 (ru) | Вакцина против вируса шмалленберга (sbv), способы ее получения и применения | |
| MX2022004836A (es) | Vacunas mejoradas para la papilomatosis respiratoria recurrente y métodos para su uso. |